Is hyperbaric oxygen or ozone effective in experimental endocarditis?

Ozkan M. T. A., Vural A., Cicek O. F., Yener A. U., ÖZCAN S., Toman H., ...More

JOURNAL OF SURGICAL RESEARCH, vol.202, no.1, pp.66-70, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 202 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1016/j.jss.2015.12.006
  • Journal Name: JOURNAL OF SURGICAL RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.66-70
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

Background: Infective endocarditis, a disease with high mortality and morbidity, is most commonly caused by Staphylococcus aureus; mortality and morbidity further increase in the presence of methicillin-resistant strains of S. aureus. Linezolid is the first of the oxazolidinones, a new antibiotic group that has been approved for the treatment of infections caused by gram-positive cocci. Linezolid reduces the quantity of microorganisms in vegetation to some extent; in addition, the use of hyperbaric oxygen (HBO) and ozone (O-3) therapies is likely to improve targeted antibacterial effect.